LaFleur & Godfrey LLC trimmed its stake in shares of STERIS plc (NYSE:STE – Free Report) by 11.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,927 shares of the medical equipment provider’s stock after selling 4,800 shares during the period. LaFleur & Godfrey LLC’s holdings in STERIS were worth $9,137,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of STE. Steigerwald Gordon & Koch Inc. acquired a new stake in STERIS during the 3rd quarter worth about $25,000. Cloud Capital Management LLC purchased a new position in shares of STERIS in the third quarter worth approximately $29,000. Spurstone Advisory Services LLC purchased a new position in shares of STERIS in the second quarter worth approximately $29,000. Geneos Wealth Management Inc. raised its holdings in shares of STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the period. Finally, TruNorth Capital Management LLC purchased a new stake in shares of STERIS in the 3rd quarter valued at approximately $37,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.
STERIS Price Performance
NYSE STE opened at $250.55 on Monday. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $24.57 billion, a PE ratio of 34.94 and a beta of 1.03. STERIS plc has a 12-month low of $204.90 and a 12-month high of $269.44. The company has a 50 day moving average price of $256.10 and a two-hundred day moving average price of $251.48.
STERIS Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s dividend payout ratio is currently 35.15%.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.
Read Our Latest Stock Report on STERIS
About STERIS
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Featured Articles
- Five stocks we like better than STERIS
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
